Comprehensive
training and support programs tailored to your facility’s needs.
Comprehensive Therapy
Implementation Program
We are here to support your program from implementation, ongoing education and training through program assessment and review. Our dedicated and experienced field team includes:
Therapy Development Specialists
Portfolio Managers
Implementation Specialists
Clinical Educators
Technical Service Representatives
24/7 Clinical Support
Help-line
Your first line of defense and a trusted partner when you need it most.
Staffed by experienced clinical professionals, as well as an on-call MD and PharmD, this unique resource can assist you with clinical questions and trouble-shooting any time day or night.
By simulating the situation in question, not only can we walk you through the process step-by-step, but we can help explain how to deal with it to avoid future issues.
 
 
   
On-going Clinical
Education
We have a multitude of resources to provide you continued support and help you optimize your program.
In-person with our Clinical Education Team.
Online with our Acute Therapy Institute.
Take advantage of our new service, Sharesource Connect software, to help better understand your facility’s operational analytics and optimize your CRRT program.
24/7 Technical Support
With over 175 field personnel in the U.S., Baxter always has someone nearby you can depend on.
Our Technical Assistance Services is always available to answer your questions by phone.
Additionally, we can have an individual onsite within 48 hours, if not sooner, to service your needs.
 
 
 
 
 
 
Featured Presentation
CRRT in the Era of Drug Shortages
 
 
 
Want more information?
Speak with a Baxter representative or
connect with us at an event.
Acute Therapies Institute
This initiative brings together the kidney care
community to learn from industry experts and
share best practices.
 
 
 
The PRISMAFLEX Control Unit is intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.
Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.
Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM Renal Replacement Solution Indications and Important Risk Information

Indications
PHOXILLUM solution is indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. It may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Important Risk Information
PHOXILLUM solution can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis. PHOXILLUM solution can effect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

PRISMASOL Renal Replacement Solution Indications and Important Risk Information

Indications
PRISMASOL Renal Replacement Solution is indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolytes and acid-base imbalances. PRISMASOL Solution may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Important Risk Information
PRISMASOL Renal Replacement Solution is contraindicated in patients with known hypersensitivities to this product.
PRISMASOL Solution can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. The use of PRISMASOL Solutions containing dextrose may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation of or modification of antidiabetic therapy during treatment with PRISMASOL Solutions containing dextrose. Monitor blood glucose.
Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.